The researchers propose to develop a Canada-wide, adaptive randomized clinical platform trial to assess the effectiveness of various interventions in patients with lingering symptoms of COVID-19 ("Long COVID"). Participants will be randomized initially to 1 of 3 arms, including placebo (control) and 2 interventions. Because this is an adaptive trial, arms can be dropped if found to be ineffective and new arms can be added.
Interventions will last for 2 months and participants will be followed for an additional 4 months (6 months total). Approximately 800-1000 patients with Long COVID will be recruited across Canada. Results from this trial will accelerate the availability of high-quality, real-time evidence and solutions to enable Canada to improve the clinical care of patients with Long COVID.

开始日期2023-05-31

申办/合作机构

University Health Network

NCT05414240

/ Recruiting临床2期IIT

A Randomized, Double-blind Placebo-Controlled Study of Ibudilast for Treating Alcohol Use Disorder

This is a research study involving 6 weeks of study medication, Ibudilast or a placebo (an inactive substance) and medical management counseling to reduce or stop drinking. Ibudilast is not approved by the U.S. FDA for clinical use in the United States, but it is has been used for many years in Japan for its anti-inflammatory effects. Its use in the treatment of alcohol dependence is experimental. By reducing inflammation, Ibudilast may help some people reduce or stop drinking. We have obtained an Investigational New Drug Application (IND) approval for this study from the FDA. Ibudilast has been used clinically for 20 years in Asia for treating bronchial asthma and, more recently, for post-stroke dizziness and ocular allergies and has been shown to be safe and well tolerated.

开始日期2023-01-14

申办/合作机构

University of Pennsylvania

NCT04631471

/ Recruiting临床3期IIT

Regeneration in Cervical Degenerative Myelopathy - a Multi-centre, Double-blind, Randomised, Placebo Controlled Trial Assessing the Efficacy of Ibudilast as an Adjuvant Treatment to Decompressive Surgery for Degenerative Cervical Myelopathy

Degenerative (wear and tear arthritis of the spine) Cervical (concerning the neck) Myelopathy (injury to the spinal cord), DCM, is the most common spinal cord disorder of adulthood. In DCM, arthritis of the spine causes compression of the spinal cord.
The symptoms of DCM are often mistaken for natural consequences of ageing, including numb and clumsy hands, loss of coordination, imbalance, bladder and bowel problems. The weakness can progress to severe paralysis. Every year approximately 4 individuals in 100,000 undergo surgery for DCM; however, many more individuals are thought to suffer from DCM.
The main treatment for DCM is surgery. The aim of surgery is to create space and remove the compression of the spinal cord. This is known to prevent further injury. Unfortunately, the post-operative improvements are often incomplete and many patients remain severely disabled. Improving outcome after surgery represents an important unmet clinical need.
Clinical and preclinical findings indicate that the drug Ibudilast can stimulate neuroprotective and regenerative processes in the spinal cord. Ibudilast is well-tolerated and used to treat asthma and post-stroke dizziness in Japan and is currently being investigated for use in treating other neurological diseases.
This study will investigate whether daily oral administration of Ibudilast for a maximum of 34 weeks can improve hand function, strength, balance, urinary problems and reduce pain.
The study will initially be conducted at three sites in the UK, with more sites added as necessary. Individuals between 18-80 years old, diagnosed with DCM and scheduled for an operation for the first time will be invited to participate in the trial. The study will entail patient questionnaires and clinical assessments before surgery, shortly after surgery and 3, 6, and 12 months after surgery. Moreover, patients will undergo MRI scans pre-operatively and at 6-months postoperatively to determine whether the treatment was successful.

开始日期2021-12-22

申办/合作机构

Cambridge University Hospitals NHS Foundation Trust

100 项与异丁司特相关的临床结果

登录后查看更多信息

100 项与异丁司特相关的转化医学

登录后查看更多信息

100 项与异丁司特相关的专利（医药）

登录后查看更多信息

404

项与异丁司特相关的文献（医药）

2025-01-03·CNS & Neurological Disorders - Drug Targets

The Role of Glial Cells in Autism Spectrum Disorder: Molecular Mechanisms and Therapeutic Approaches

Article

作者: Inamdar, Aparna ; Gurupadayya, Bannimath ; Sharma, Himanshu

Abstract:Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by social communication deficits and repetitive behaviors. Emerging evidence highlights the significant role of glial cells, particularly astrocytes and microglia, in the pathophysiology of ASD. Glial cells are crucial for maintaining homeostasis, modulating synaptic function, and responding to neural injury. Dysregulation of glial cell functions, including altered cytokine production, impaired synaptic pruning, and disrupted neuroinflammatory responses, has been implicated in ASD. Molecular mechanisms underlying these disruptions involve aberrant signaling pathways, such as the mTOR pathway, and epigenetic modifications, leading to altered gene expression profiles in glial cells. Moreover, microglial activation and reactive astrocytosis contribute to an inflammatory environment that exacerbates neural circuit abnormalities. Understanding these molecular mechanisms opens avenues for therapeutic interventions. Current therapeutic approaches targeting glial cell dysfunction include anti-inflammatory agents, modulators of synaptic function, and cell-based therapies. Minocycline and ibudilast have shown potential for modulating microglial activity and reducing neuroinflammation. Additionally, advancements in gene editing and stem cell therapy hold promise for restoring normal glial function. This abstract underscores the importance of glial cells in ASD. It highlights the need for further research to elucidate the complex interactions between glial dysfunction and ASD pathogenesis, aiming to develop targeted therapies that can ameliorate the clinical manifestations of ASD.

2024-12-15·Rapid Communications in Mass Spectrometry

Equine metabolic investigation of the phosphodiesterase‐4 inhibitor ibudilast as a potential performance enhancer

Article

作者: Kal, Abdul Khader Karakka ; Subhahar, Michael Benedict ; Joseph, Marina ; Karatt, Tajudheen K. ; Graiban, Fatma Mohammed ; Philip, Moses ; Jose, Shantymol V. ; Ajeebsanu, Meleparappil Muhammed

RationalePhosphodiesterase 4 (PDE4) inhibitors are a newer class of drugs that induce bronchodilation and have anti‐inflammatory effects, making them susceptible to misuse as performance enhancers in competitive sports.MethodsThis study explores the metabolic conversion of PDE4 inhibitor ibudilast in thoroughbred horses after oral administration and in vitro using equine liver microsomes and Cunninghamella elegans. A liquid chromatography‐high resolution mass spectrometry method was used to postulate the plausible structures of the detected metabolites.ResultsA total of 20 in vivo metabolites were identified under experimental conditions, including 12 Phase I and 8 Phase II conjugated metabolites. Phase I metabolites were predominantly formed through hydroxylation (mono‐, di‐, and tri‐hydroxylation). Demethylated metabolites were also identified during this investigation. Additionally, the research detected Phase II metabolites conjugated with glucuronic and sulfonic acids.ConclusionsThe data presented here can assist in detecting the PDE4 inhibitor ibudilast and uncover its illicit use in competitive sports.

2024-09-01·Genes & Genomics

Actn2 defects accelerates H9c2 hypertrophy via ERK phosphorylation under chronic stress

Article

作者: Chen, Peng ; Sheng, Mingchen ; Yu, Youjia ; Wang, Ye ; Wu, Jiayi ; Hu, Li ; Huang, Shuainan ; Chen, Feng ; Wang, Kang ; Wan, Hua ; Han, Xing ; Wang, Jie

BACKGROUNDIn humans, ACTN2 mutations are identified as highly relevant to a range of cardiomyopathies such as DCM and HCM, while their association with sudden cardiac death has been observed in forensic cases. Although ACTN2 has been shown to regulate sarcomere Z-disc organization, a causal relationship between ACTN2 dysregulation and cardiomyopathies under chronic stress has not yet been investigated.OBJECTIVEIn this work, we explored the relationship between Actn2 dysregulation and cardiomyopathies under dexamethasone treatment.METHODSPrevious cases of ACTN2 mutations were collected and the conservative analysis was carried out by MEGA 11, the possible impact on the stability and function of ACTN2 affected by these mutations was predicted by Polyphen-2. ACTN2 was suppressed by siRNA in H9c2 cells under dexamethasone treatment to mimic the chronic stress in vitro. Then the cardiac hypertrophic molecular biomarkers were elevated, and the potential pathways were explored by transcriptome analysis.RESULTSActn2 suppression impaired calcium uptake and increased hypertrophy in H9c2 cells under dexamethasone treatment. Concomitantly, hypertrophic molecular biomarkers were also elevated in Actn2-suppressed cells. Further transcriptome analysis and Western blotting data suggested that Actn2 suppression led to the excessive activation of the MAPK pathway and ERK cascade. In vitro pharmaceutical intervention with ERK inhibitors could partially reverse the morphological changes and inhibit the excessive cardiac hypertrophic molecular biomarkers in H9c2 cells.CONCLUSIONOur study revealed a functional role of ACTN2 under chronic stress, loss of ACTN2 function accelerated H9c2 hypertrophy through ERK signaling. A commercial drug, Ibudilast, was identified to reverse cell hypertrophy in vitro.

项与异丁司特相关的新闻（医药）

2024-12-06

·EndPoints

Teva to divest business venture in Japan; Layoffs at Rome Therapeutics

Plus, news about Cyclacel Pharmaceuticals, MediciNova and Revolution Medicines: Teva will divest its Japan business venture to private equity firm: The company said Friday that it agreed to transfer all shares of Teva Takeda and its subsidiary Teva Takeda Yakuhin — its businesses that sell generics in Japan — to JKI, a fund managed by J-Will Partners. According to Teva, the divestment will allow Teva to focus on its innovative medicines business in Japan. — Katherine Lewin Rome Therapeutics’ layoffs: The “dark genome” biotech is prioritizing its pipeline and letting go of 17 employees, according to CEO Rosana Kapeller’s LinkedIn post on Thursday. The company is now focused on autoimmune and neurodegenerative diseases. “As we advance both of these programs toward the clinic, we’ll be deprioritizing unrelated areas of dark genome research,” she wrote. — Kyle LaHucik Cyclacel announces plan for strategic alternatives: The company is reviewing options on an “expedited basis” in order to preserve cash, adding that the board also told management to reduce operating costs. Its stock $CYCC was down about 12% on Friday. — Katherine Lewin MediciNova to present interim analysis for ALS drug: MediciNova CMO Kazuko Matsuda said in a statement there’s a “a positive correlation between the 6-month and 12-month data” for ibudilast in a Phase 2/3 trial that enrolled patients with amyotrophic lateral sclerosis. The data are set to be presented this week at the International Symposium on ALS/MND in Canada, and full trial results are expected in 2026. — Katherine Lewin Revolution Medicines raised a total of $862.5 million in its public offering, far more than the $600 million it initially set out to bring in. — Jaimy Lee

并购临床结果

2024-12-05

·GlobeNewswire-Health Care

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

LA JOLLA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces the study update and interim analysis results from the Company’s COMBAT-ALS Phase 2b/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) will be presented at the 35th International Symposium on ALS/MND held December 6-8, 2024 in Montreal, Canada. The highlights of the presentation, titled, “COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Trial Update and Interim Analysis Results” (Abstract # 302), include: Study Update: As of November 15, 2024, a total of 217 participants have been enrolled and 183 participants were assigned to either MN-166 or placebo group.Pre-defined interim analysis was conducted to evaluate the correlation between the 6-month and 12-month data and assess the 12-month double-blind phase trial design.A subset of patients from the full analysis set who had ALSFRS-R data at 6 months and at least one post-6-month data point. Correlation analysis of the Combined Assessment of Function and Survival (CAFS) scores at 6 and 12 months as well as modified CAFS scores and ALSFRS-R scores were evaluated.Positive correlations were observed between the 6-month and 12-month data for CAFS score (0.71), modified CAFS score (0.70), and ALSFRS-R (0.69). [Note: Values in parentheses are Spearman Rank Correlation coefficients]Positive correlations were also observed for Bulbar score (0.74), Fine motor score (0.71), and Gross motor score (0.67), but not for Respiratory score. [Note: Values in parentheses are Spearman Rank Correlation coefficients]Interim analysis results were reviewed and validated by an external independent Data Safety Monitoring Board (DSMB), which recommended that the trial continue as per the protocol. MediciNova CMO and Director Kazuko Matsuda commented, "The interim analysis showed a positive correlation between the 6-month and 12-month data. We considered a change in the treatment period, decided to continue the trial with the current treatment plan based on the DSMB's recommendation. We believe these results will be valuable in designing studies for rapidly progressing diseases like ALS. As of mid-November 2024, over 200 patients have been enrolled and more than 180 patients assigned, if we continue to actively enroll in the COMBAT-ALS study, we expect to complete patient assignments by June 2025 with trial results expected in 2026. Concurrently, we have been supporting continued treatment for those patients wishing to continue MN-166 treatment after the 6-month open-label phase via the FDA's Expanded Access Program (EAP). Next year, the NIH-funded, large-scale Expanded Access Program trial is set to begin, and we look forward to the opportunity to provide access to MN-166 to more ALS patients.” About MN-166 (ibudilast) MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), progressive MS (multiple sclerosis), and DCM (degenerative cervical myelopathy); and is also in development for glioblastoma, Long COVID, CIPN (chemotherapy-induced peripheral neuropathy), and substance use disorder. In addition, MN-166 (ibudilast) was evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS). About MediciNova MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants. Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166, MN-001, MN-221, and MN-029. These forward-looking statements may be preceded by, followed by, or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2023 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements. INVESTOR CONTACT: David H. Crean, Ph.D.Chief Business OfficerMediciNova, Incinfo@medicinova.com

临床2期临床3期临床结果

2024-11-20

·PRNewswire

WideTrial Supports NIH-Funded Expanded Access Program for Investigational ALS Drug

Program to provide investigational drug to ALS patients who would otherwise be ineligible for clinical trials SANTA CLARA, Calif., Nov. 20, 2024 /PRNewswire/ -- WideTrial, an innovator of expanded access program (EAP) solutions, announced its participation in an NIH-funded collaboration to provide pre-approval access to an investigational ALS drug. The program will offer access to ibudilast, an experimental drug being studied for its potential to slow the progression of ALS, to patients who are ineligible for clinical trials. Continue Reading WideTrial is participating in a program to provide pre-approval access to an investigational ALS drug. It will offer access to ibudilast, an experimental drug being studied for its potential to slow the progression of ALS, to patients who are ineligible for clinical trials. The program is funded by a $22 million grant from the National Institute of Neurological Disorders and Stroke (NINDS) and will be led by Dr. Bjorn Oskarsson at Mayo Clinic's ALS Center of Excellence in Jacksonville, Florida. The program is funded by a $22 million grant from the National Institute of Neurological Disorders and Stroke (NINDS) and will be led by Dr. Bjorn Oskarsson at Mayo Clinic's ALS Center of Excellence in Jacksonville, Florida. It aims to enroll 200 ALS patients across all three Mayo Clinic centers and other participating institutions. WideTrial will support the program by engaging a growing group of ALS specialists, enabling greater diversity of patient location and background in the treatment program. The study aims to measure ibudilast's effect on ALS progression using a blood test that shows whether neurofilament protein levels have changed in patients with ALS. High levels of neurofilament proteins may indicate damage in neurons. "We are pleased to support this important initiative to expand access to investigational ALS treatments," said Jess Rabourn, CEO of WideTrial. "At WideTrial, we believe every patient deserves a chance to explore potential therapies, regardless of their eligibility for traditional research trials. The collaboration is part of our commitment to empowering patients and providers with solutions that democratize access to research-stage medicines." WideTrial's expertise in expanded access programs will help ensure the efficient and compliant implementation of the NIH-funded study. Expanded Access provides a pathway for patients with serious or life-threatening conditions who cannot participate in clinical trials to access investigational drugs. Group-level Expanded Access Programs (EAPs) allow a greater number of patients and their physicians to explore a new investigational treatment under a well-designed protocol and supply chain, working in harmony with the continued clinical development of the treatment. When integrated into the drug development cycle, EAPs offer benefits such as wider patient engagement, increased chances of discovering response-predictive biomarkers, and information that leads to more targeted pivotal trials. About WideTrial WideTrial is an integrated service and technology platform that delivers scalable, group-level Expanded Access programs (EAPs) that are easy to participate in and improve patient access to investigational treatments. The company's mission is to bridge the gap between patients and potentially life-saving therapies by streamlining and simplifying the EAP process. WideTrial's expertise and commitment to patient-centric solutions enable healthcare providers and drug developers to efficiently and compliantly offer expanded access to investigational drugs. To learn more, visit widetrial.com. Media Contact : WideTrail: Francis Greenleaf | [email protected] ZingPR for WideTrail: Tim Cox | [email protected] SOURCE WideTrial Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床研究

100 项与异丁司特相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01385	异丁司特	R03DC04	DB05266

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
脑血管疾病	韩国	-	2002-09-19
哮喘	日本	KYORIN Pharmaceutical Co., Ltd.	1989-01-17
脑出血	日本	KYORIN Pharmaceutical Co., Ltd.	1989-01-17

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脊髓型颈椎病	临床3期	-	MediciNova, Inc.	2022-03-01
肌萎缩侧索硬化	临床3期	加拿大	MediciNova, Inc.	2020-05-28
肌萎缩侧索硬化	临床3期	美国	MediciNova, Inc.	2020-05-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04057898 (COMBAT-ALS, GlobeNewswire) 人工标引	临床2/3期	肌萎缩侧索硬化	183	MN-166	範艱構築製糧窪範築襯(膚窪鹹壓憲廠願膚製築) = Positive correlations were observed between the 6-month and 12-month data for CAFS score (0.71), modified CAFS score (0.70), and ALSFRS-R (0.69). [Note: Values in parentheses are Spearman Rank Correlation coefficients] Positive correlations were also observed for Bulbar score (0.74), Fine motor score (0.71), and Gross motor score (0.67), but not for Respiratory score. [Note: Values in parentheses are Spearman Rank Correlation coefficients] 廠遞糧膚鹽齋鹽願網鏇 (製獵構齋鏇襯衊膚選顧 )	积极	2024-12-05
				placebo
NCT03594435 (CTgov)	临床2期	酒精使用障碍	102	Ibudilast (Ibudilast)	鹹餘夢願鹹餘構製夢構(鹽網積衊選壓遞觸壓糧) = 簾製選範範艱獵衊餘鑰夢觸夢範憲選繭齋繭壓 (壓齋夢醖製鏇鑰壓願醖, 鬱築顧獵選糧壓選願鏇 ~ 淵鏇構範醖齋鹹襯齋鹽) 更多	-	2024-11-27
				Placebo oral capsule (Placebo Oral Capsule)	鹹餘夢願鹹餘構製夢構(鹽網積衊選壓遞觸壓糧) = 鹽範鹽膚醖窪夢醖壓鏇夢觸夢範憲選繭齋繭壓 (壓齋夢醖製鏇鑰壓願醖, 鹹淵選衊膚艱廠鬱醖築 ~ 構衊鏇憲選鏇願壓餘蓋) 更多
NCT02714036 (CTgov)	临床1/2期	肌萎缩侧索硬化	35	ibudilast (Regular)	繭餘窪醖醖襯鹹願構廠(願積顧簾醖廠網鬱顧醖) = 醖顧遞繭淵餘襯淵蓋膚淵醖製衊鹹壓襯醖醖餘 (鹽蓋衊網網夢鏇範餘窪, 艱遞鏇廠觸夢積簾憲顧 ~ 積鑰獵淵選簾艱醖簾獵) 更多	-	2024-09-24
				ibudilast (Flexible)	簾遞餘醖廠糧繭積蓋鏇(觸繭膚鏇鏇繭簾選網觸) = 觸鏇醖淵淵選艱齋夢鏇窪襯鏇鏇膚鑰齋遞遞網 (蓋齋鏇遞鬱鬱願壓觸網, 觸餘壓壓製艱鹹鏇觸膚 ~ 鏇衊鹹繭選襯構鬱壓艱) 更多
NCT03782415 (ASCO2024) 人工标引	临床1/2期	胶质母细胞瘤 CD74 expression	62	Ibudilast temozolomide	(餘獵鏇糧鹹築淵鏇範築) = Ibudilast 50 mg BID 餘憲廠醖鬱廠淵築簾艱 (繭糧構觸獵壓鹽選鏇構 )	积极	2024-05-24
				Ibudilast temozolomide
NCT03782415 (GlobeNewswire) 人工标引	临床2期	胶质母细胞瘤一线	62	MN-166+temozolomide	-	积极	2023-11-19
				MN-166+temozolomide (newly diagnosed GBM)	(範製壓蓋製選構窪願廠) = 積積艱觸膚鏇鹽築鬱糧廠壓觸範夢積鏇願構齋 (觸糧築簾積觸鑰願襯構 )
MN166-GBM-1201 (SNO2023)	临床1/2期	胶质母细胞瘤 CD3+ \| CD74 \| CD11b ... 更多	62	MN-166 and TMZ combination therapy	衊鹽鹹壓夢構餘壓鏇艱(鬱餘網願繭醖齋糧壓範) = 膚鹽淵齋餘鹽網顧壓繭窪範願獵築積網鏇鏇襯 (選鏇網齋窪鹽繭顧鏇顧 )	积极	2023-11-10
ACTRIMS2023	N/A	-	-	Ibudilast	(簾餘壓鹽糧製鹹膚夢鹹) = 衊鬱窪壓鹹膚艱齋鹽鹽醖醖艱糧簾願製觸餘膚 (壓鹽鹹蓋醖蓋蓋壓艱艱 ) 更多	-	2023-05-30
				Placebo	(簾餘壓鹽糧製鹹膚夢鹹) = 積觸製構壓簾廠獵餘醖醖醖艱糧簾願製觸餘膚 (壓鹽鹹蓋醖蓋蓋壓艱艱 ) 更多
NCT04429555 (Corporate Publications) 人工标引	临床2期	新型冠状病毒感染 \| 成人呼吸窘迫综合征	34	MN-166	(膚鏇製繭衊獵醖壓醖顧) = 膚積觸獵鹹繭觸憲簾醖夢鬱壓願壓選淵遞襯糧 (膚壓壓壓壓糧醖鬱鹹鬱 ) 更多	积极	2022-06-08
				Placebo	(膚鏇製繭衊獵醖壓醖顧) = 餘積鹹遞廠選製鹽範鏇夢鬱壓願壓選淵遞襯糧 (膚壓壓壓壓糧醖鬱鹹鬱 ) 更多
NCT02238626 (IBU-ALS-1201, CTgov)	临床2期	肌萎缩侧索硬化	70	MN-166+riluzole (MN-166)	餘製憲遞鑰製選顧鹽淵(遞蓋蓋廠鹹憲憲廠選淵) = 選餘願餘築壓鑰獵繭鬱憲醖窪選淵遞選積簾簾 (淵鏇鹽鹽膚鏇網選窪艱, 艱壓鏇鏇膚構衊夢壓範 ~ 顧夢餘醖醖鹹憲遞築衊) 更多	-	2021-11-05
				Placebo (for MN-166)+riluzole (Placebo (for MN-166))	鬱鑰鬱遞製衊簾鹹積襯(夢選蓋顧繭繭鑰壓膚鏇) = 積願鏇遞範衊鏇夢簾齋憲齋艱獵鬱壓艱齋鏇願 (廠網顧範襯膚襯積願鏇, 製膚網積鑰夢鹹築醖鏇 ~ 醖構網膚壓鹹繭鏇鑰構)
NCT01982942 (SPRINT-MS, ECTRIMS2021)	临床2期	慢性进行性多发性硬化	-	Ibudilast	繭顧遞願餘鏇淵鑰襯鏇(襯繭餘繭範壓憲願選壓) = 蓋網願醖齋鑰鬱網醖獵壓鏇簾襯艱構選願構鹽 (網鹹襯鹹網廠觸願膚鑰, 0.20)	-	2021-10-12
				Placebo	繭顧遞願餘鏇淵鑰襯鏇(襯繭餘繭範壓憲願選壓) = 壓壓淵鑰鏇膚鬱襯鬱蓋壓鏇簾襯艱構選願構鹽 (網鹹襯鹹網廠觸願膚鑰, 0.20)